104 completed, 13 terminated, 5 unknown, 4 recruiting. 47 Phase 2, 40 Phase 1, 23 Not applicable, 20 Phase 3, 10 Phase 4.
Follow Nelfinavir: new trials by email Literature Review of Nelfinavir trials Research Report on Nelfinavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autophagy Maintenance (AUTOMAIN) Hydroxychloroquine, Nelfinavir, Bevacizumab - Ovarian Cancer | Phase 2 | Recruiting | Medical University of South Carolina | 38 | 2025-12-18 | 2025-12-22 |
| Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Nelfinavir - Myelofibrosis, Myelofibrosis; Anemia | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 10 | 2025-09-16 | 2026-05-04 |
| COAST Therapy in Advanced Solid Tumors and Prostate Cancer Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir - Prostate Cancer Recurrent, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 76 | 2022-03-03 | 2026-05-13 |
| Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery Cisplatin, External Beam Radiation Therapy, Nelfinavir - Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 25 | 2020-08-07 | 2026-05-20 |
| Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Bortezomib, Metformin Hydrochloride, Nelfinavir Mesylate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 9 | 2019-04-17 | 2024-08-22 |
| A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia Nelfinavir - Cervical Dysplasia | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2018-11-07 | 2020-11-12 | |
| Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix Nelfinavir, Cisplatin, Pelvic EBRT and Brachytherapy - Carcinoma Cervix,Stage III | Phase 3 | Completed | Tata Memorial Hospital | 348 | 2018-01-16 | 2026-02-24 |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis - Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Terminated | University of Washington | 21 | 2017-06-09 | 2022-06-22 |
| Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Laboratory Biomarker Analysis, Nelfinavir Mesylate - Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma | Phase 2 | Completed | AIDS Malignancy Consortium | 36 | 2017-03-13 | 2025-12-17 |
| Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma MLN9708, Nelfinavir - Neoplasms, Lymphoma | Phase 1 | Withdrawn | Dartmouth-Hitchcock Medical Center | 2016-08-01 | 2018-02-06 | |
| Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 nab-paclitaxel, 60Gy in 30#, 50.4Gy in 28# - Pancreatic Neoplasms (Locally Advanced Non-metastatic) | Phase 1 / Phase 2 | Completed | University of Oxford | 159 | 2016-03-01 | 2024-07-25 |
| A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA) Nelfinavir, Cisplatin - Uterine Cervix Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 6 | 2015-02-01 | 2020-04-06 |
| Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma Nelfinavir, bortezomib, Dexamethasone - Myeloma | Phase 2 | Completed | Swiss Cancer Institute | 34 | 2014-12-02 | 2019-06-26 |
| Nelfinavir in Systemic Lupus Erythematosus Nelfinavir - Systemic Lupus Erythematosus | Phase 2 | Terminated | Northwell Health | 15 | 2014-09-01 | 2020-02-24 |
| Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Nelfinavir (Viracept®) 1250 mg, Chemoradiation - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 18 | 2014-07-01 | 2023-07-25 |
| Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Nelfinavir - Non-Hodgkin Lymphoma, Hodgkin Lymphoma | Early Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2014-07-01 | 2016-06-10 |
| Stereotactic Body Radiation With Nelfinavir for Oligometastases Nelfinavir, Stereotactic Body Radiation (SBRT) - Oligometastases | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 38 | 2014-01-08 | 2021-07-12 |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride - Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma | Phase 2 | Completed | University of Nebraska | 11 | 2013-09-06 | 2023-10-10 |
| Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma Nelfinavir, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Swiss Cancer Institute | 33 | 2012-02-23 | 2022-07-07 |
| Radical Lung Radiotherapy Plus Nelfinavir nelfinavir, Radical Radiotherapy - Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Oxford University Hospitals NHS Trust | 2012-02-01 | 2016-06-23 |
Showing 20 of 132. Sign in to see all of them.
HIV Infections (89) · AIDS-Related Opportunistic Infections (6) · Neoplasms (6) · Acquired Immunodeficiency Syndrome (5) · Lipodystrophy (5) · Carcinoma, Non-Small-Cell Lung (4) · Pancreatic Neoplasms (4) · Sarcoma, Kaposi (4) · Disease Progression (3) · Lymphoma (3) · Multiple Myeloma (3) · Sarcoma (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Renal Cell (2) · Glioblastoma (2)
National Institute of Allergy and Infectious Diseases (NIAID) (34) · Agouron Pharmaceuticals (12) · Glaxo Wellcome (8) · Bristol-Myers Squibb (7) · Abramson Cancer Center at Penn Medicine (6) · Hoffmann-La Roche (5) · Pfizer (5) · Mayo Clinic (4) · Merck Sharp & Dohme LLC (3) · Swiss Cancer Institute (3) · University of Iowa (3) · Abbott (2) · Boehringer Ingelheim (2) · Centers for Disease Control and Prevention (2) · Gilead Sciences (2)
United States (115) · Puerto Rico (21) · Canada (10) · Switzerland (4) · United Kingdom (4) · Brazil (3) · Italy (3) · Netherlands (3) · South Africa (3) · Spain (3) · Thailand (3) · Australia (2) · Dominican Republic (2) · France (2) · Germany (2)
Diane Havlir (3) · Scott Hammer (3) · Andrew D. Badley, M.D. (2) · Andrew Wiznia (2) · Chi Lin (2) · Courtney Fletcher (2) · Abhimanyu Garg, M.D. (1) · Alexander Lin, MD (1) · Alice Stek (1) · Amit Maity (1) · Andrea Kovacs (1) · Andrew D Carr, MD (1) · Andrew Urban, MD (1)
PMID 18090046, PMID 24326304, PMID 10601506, PMID 10954886, PMID 11023461, PMID 11069252, PMID 11306155, PMID 11372025, PMID 11880966, PMID 11927734, PMID 12195349, PMID 12934177, PMID 14668455, PMID 14668456, PMID 14982784, PMID 15002082, PMID 15031785, PMID 15187476, PMID 15213559, PMID 15295692, PMID 15356820, PMID 15687448, PMID 15750390, PMID 16048950, PMID 16048984, PMID 16103764, PMID 16131307, PMID 16159645, PMID 16192247, PMID 16220085, PMID 16249704, PMID 16267764, PMID 16514303, PMID 16810109, PMID 17174704, PMID 17507321, PMID 17662759, PMID 17726714, PMID 17893156, PMID 17981652, PMID 18176329, PMID 18226670, PMID 18366444, PMID 18398973, PMID 18474496, PMID 18977721, PMID 19758095, PMID 20418798, PMID 20467286, PMID 21134574
P30CA036727 (2), 2004 (1), 2UM1CA121947 (1), P30CA015704 (1), R01DK056583 (1), R01HL065953 (1), R01MH058076 (1)